European review for medical and pharmacological sciences最新文献

{"title":"Trends in bacterial and fungal bloodstream infections in Southeast Asia: A review of blood culture pathogens (2018-2024).","authors":"A S Karajacob, F Ibrahim, S F Syed Omar, N S Zambry, S T Tay","doi":"10.26355/eurrev_202507_37328","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37328","url":null,"abstract":"<p><p>Bloodstream infections (BSIs) pose a significant health burden in clinical settings, contributing to high morbidity and mortality rates worldwide. This review aims to analyze the trends of bacterial and fungal BSI and blood culture pathogen profiles reported in adolescents and adults in Southeast Asian (SEA) countries, drawing from published studies between 2018 and 2024. A comprehensive literature search was conducted via PubMed, Scopus, Web of Science, and Cochrane Library, analyzing 23 studies that included 14,512 patients from 7 SEA countries. The narrative review highlighted various prevalence rates of bacterial and fungal BSIs among different patient groups: those with indwelling catheters (0.6%-46.9%), sepsis (12.6%-44.5%), and hospitalized patients with other comorbidities (1.1%-29.5%). Blood culture findings revealed that Escherichia coli and Staphylococcus aureus were the most commonly isolated gram-negative and gram-positive bacteria, respectively, while Candida species emerged as the predominant fungal pathogen. Notably, non-albicans Candida species were more common than Candida albicans in SEA fungemia patients. The overall findings of pathogen distribution in blood cultures from SEA patients are consistent with global surveillance data; however, distinct regional pathogens endemic to SEA, particularly Burkholderia pseudomallei and Talaromyces marneffei, were also identified. Significant gaps exist in determining bacterial and fungal BSI epidemiology among vulnerable populations, including the acquisition sources, risk factors, antimicrobial resistance patterns, and mortality rates across the SEA region. Overcoming challenges arising from inadequate surveillance and diagnostic capabilities could significantly reduce the BSI burden in the region.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-AbstractNEW-BIS.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"356-374"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ezetimibe reduces α-tocopherol levels in type 2 diabetes.","authors":"A Toffalini, N Vigolo, N Rolli, E Paviati, M Gelati, E Danese, G Zoppini","doi":"10.26355/eurrev_202507_37329","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37329","url":null,"abstract":"<p><p>OBJECTIVE: α-tocopherol has a protective role against free radical-induced damage. The intestinal absorption of α-tocopherol is in part carried out by Nieman-Pick1-like1 protein, which is the target of ezetimibe, a drug used for the treatment of hypercholesterolemia. Ezetimibe is frequently prescribed to patients with type 2 diabetes in combination with statins. Therefore, the aim of the present study was to investigate the impact of ezetimibe treatment on the blood level of α-tocopherol. MATERIALS AND METHODS: Two hundred patients affected by type 2 diabetes, regularly attending the diabetes clinic, were recruited. All patients should not have received vitamin supplements in the six months preceding the study. α-tocopherol was measured by reverse-phase high-performance liquid chromatography with UV detection. Other laboratory parameters were determined by standard laboratory procedures. Patients were analyzed according to ezetimibe treatment. A linear multivariate regression analysis was used to estimate the factors associated with α-tocopherol level. RESULTS: The majority of patients were on ezetimibe/statin treatment. Patients taking ezetimibe showed a significantly lower α-tocopherol level, 29.9±5.7 vs. 32.9±7.0 μmol/L (p=0.006) compared to those not taking the drug. Ezetimibe was significantly and negatively associated with α-tocopherol level in the multivariate analysis (β standardized coefficient = -.217, p = .002). CONCLUSIONS: Treatment with ezetimibe can reduce α-tocopherol plasma levels by inhibiting the Niemann-Pick C1-like protein. Future studies are required to address the clinical implications of this finding.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-2-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"375-380"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anterior knee laxity and ACL magnetic resonance signals in healthy and ACL-reconstructed knees following exercise.","authors":"L Moretti, M Coviello, G Maccagnano, G D Cassano, A Carlet, E Favilla, B Moretti, G Solarino","doi":"10.26355/eurrev_202507_37327","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37327","url":null,"abstract":"<p><strong>Objective: </strong>The study compared anterior knee laxity and anterior cruciate ligament magnetic resonance signals between healthy and anterior cruciate ligament reconstruction (ACLR) knees after exercise to verify differences. This research can guide future training to reduce the risk of reinjury.</p><p><strong>Materials and methods: </strong>Fifty-four male footballers between June and August 2022 were enrolled in this case-control study. Subjects who underwent ACLR in the previous 3 years (study group) were compared with healthy volunteers (control group). Each group consisted of twenty-seven patients. Data recorded were anterior tibial translation (ATT) expressed in millimeters using an arthrometer and the ratio of ACL to fat tissue signal intensity using magnetic resonance imaging. Measurements were collected at T0 (at rest), T1 (after 40 minutes of linear running of 3.5 miles), and T2 (after 90 minutes of a regular football match).</p><p><strong>Results: </strong>No statistical difference was observed in demographic pre-analysis features. No difference was indicated between the two groups according to ATT. Conversely, ACL natives demonstrated significant increases in the ratio of ACL to fat tissue signal intensity when compared with ACLR in the three different measurements. Regarding differences within each group, we demonstrated that anterior knee laxity increased in both groups after 90 minutes of a regular football match. The ACL MRI signal did not differ in the study group, but it increased in the control group after exercise.</p><p><strong>Conclusions: </strong>Although exhibiting distinct MRI signals, ACL-reconstructed tendons show similar post-exercise joint laxity as healthy ligaments. Looking ahead, leveraging specific insights could help tailor training sessions for preventive purposes.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"349-355"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis.","authors":"M Minozzi, S Gerli, G C Di Renzo, E Papaleo, A Ferrari","doi":"10.26355/eurrev_202507_37337","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37337","url":null,"abstract":"<p><p>The article \"The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis\" by M. Minozzi, S. Gerli, G.C. Di Renzo, E. Papaleo, A. Ferrari, published in Eur Rev Med Pharmacol Sci 2008; 12 (1): 59-65-PMID: 18401974 has been retracted by the Authors in accordance with the Publisher and the Editor in Chief. Following some concerns raised by a third party regarding a possible high degree of textual similarity with a previously published paper, the journal has started an investigation. The authors were informed of the ongoing investigation and were asked to provide original data and clarify several other issues. In response, the authors requested the retraction of the manuscript, citing discrepancies related to the article and expressing a lack of confidence in the accuracy of the information submitted. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/477.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"347"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Concern.","authors":"N Authors Listed","doi":"10.26355/eurrev_202507_37339","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37339","url":null,"abstract":"<p><p>The Editor in Chief and the Publisher are issuing an expression of concern regarding the following article: Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte and embryo quality in PCOS patients having a normal insulin response. Eur Rev Med Pharmacol Sci. 2011 Apr; 15(4): 452-457. PMID: 21608442. This Expression of Concern is issued following a notification from a third party concerning a potential conflict of interest involving Dr. Unfer's role at Loli Pharma, the company marketing inositol-based products. This expression of concern aims to notify a possible bias arising from an undeclared conflict of interest. The authors have been notified of both the ongoing investigation and the publication of this notice. https://www.europeanreview.org/article/929.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"348"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding pharmacogenetics and metabolic panels in Jordanian women with polycystic ovary syndrome: a case-control study.","authors":"A Yehya, A M Rababa'h, J Hamadneh, C L Shaffer","doi":"10.26355/eurrev_202506_37276","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37276","url":null,"abstract":"<p><p>OBJECTIVE: This study aimed to assess the metabolic profiles and the frequency of the Serine/threonine kinase 11 (STK11) rs8111699 single-nucleotide polymorphism (SNP) among Jordanian women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS Ninety Jordanian women with PCOS and ninety healthy controls participated in the study. Metabolic characteristics were recorded, and direct sequencing was used to identify STK11 SNP genotypes. RESULTS: Among the PCOS patients, 23 (31.1%) had the wild-type (CC) genotype, while 39 (46.6%) and 28 (35.5%) had heterozygous (CG) and homozygous (GG) genotypes, respectively. There was no statistically significant difference in the genotype and allele distribution between the cases and controls (p=0.264 and p<0.702, respectively). Women carrying the minor G allele had poor metabolic profiles and more severe clinical features. CONCLUSIONS: The findings support the importance of early detection of PCOS, especially in high-risk populations, to enable timely preventive interventions. The interplay between genetic and metabolic profiles offers guidance for improving treatment outcomes in women with PCOS.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-14056.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"339-346"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective comparison of functional outcomes in open partial laryngectomy vs. total laryngectomyfor locally advanced (T3, T4) laryngeal cancer.","authors":"J Pies, S Hackenberg, M Scheich, T Meyer, A Scherzad, M Goncalves","doi":"10.26355/eurrev_202506_37271","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37271","url":null,"abstract":"<p><p>OBJECTIVE: Open partial laryngectomy (pLE), in cases not suited for transoral resection, aims to provide an oncologically safe resection, maintaining laryngeal function without the need for permanent tracheostomy. In cases requiring extensive resection, debate remains about whether pLE is feasible with a functional outcome or if total laryngectomy (tLE) is preferable. MATERIALS AND METHODS: This monocentric retrospective cohort study evaluated the resection of locally advanced (T3, T4) laryngeal carcinoma (LC) performed via open pLE or tLE between November 2010 and August 2023. Transoral resections, T1 and T2 cases were excluded. The presence of tracheostomy, the rate of oral feeding, the ability to phonate, and the oncologic outcome were assessed. RESULTS: The outcome of 38 pLEs and 56 tLEs was assessed. Adjuvant therapy was administered in 76% (n=29/38) pLEs and 47% (n=26/56) tLEs. While the oncologic results remained comparable between the two procedures (negative margins: p = 0.349; 5-year overall survival: p = 0.421), total laryngectomy (tLE) achieved better functional outcomes. Swallowing ability was markedly better after tLE (pLE vs. tLE: 39.5% vs. 91%, p < 0.001), particularly in patients with T4 tumors (pLE vs. tLE: 14% vs. 89%, p < 0.001) and in those over 65 years (pLE vs. tLE: 14% vs. 100%; p < 0.001). Overall, aspiration was the most frequent post-therapeutic complication after pLE, preventing unassisted oral intake in 58% of cases (22/38). The tracheostomy could be closed in 26% (n=10/38) of pLE-patients, at a median of 6.57 months (range 0.6-24 months). Consequently, after pLE 74% (n=28/38) of patients retained their tracheostomy at a median follow-up of 4 years. CONCLUSIONS: The low rates of tracheostoma closure, low rates of oral feeding over a median of 4 years, and R0 resection status of T4 tumors after pLE compared to tLE suggest patients with locally advanced LC are better suited for tLE.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-1.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"289-300"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra- and peri-meniscal polynucleotide injections for the treatment of symptomatic degenerative meniscus of the knee: 1-year findings from a prospective clinical trial.","authors":"G Anzillotti, P Conte, E M Bertolino, A Ferrero, B Di Matteo, M Vacca, M Di Martino, D Altomare, N Magarelli, E Lanza, P Verdonk, E Kon","doi":"10.26355/eurrev_202506_37273","DOIUrl":"10.26355/eurrev_202506_37273","url":null,"abstract":"<p><p>OBJECTIVE: Degenerative meniscal lesions consist of an alteration of the meniscal structure, eventually leading to pain and dysfunction. In the absence of mechanical symptoms, meniscectomy should be considered the last resort. Polynucleotides represent a novel treatment option which have shown promising results in different fields, including knee osteoarthritis. Hence, this study aimed to evaluate the safety and efficacy of a cycle of intra- and peri-meniscal polynucleotide injections for the treatment of degenerative meniscus. MATERIALS AND METHODS: This prospective study included 30 patients aged 25-65 with degenerative meniscal tears confirmed by MRI. Eligible patients were treated with three intra- and peri-meniscal injections of polynucleotides, administered with a two-week time interval under ultrasound guidance. The primary outcome was improvement in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS) by at least 10 points from baseline to 12-month follow-up. Secondary outcomes included Visual Analog Scale (VAS) for pain, the International Knee Documentation Committee (IKDC) score, and the Tegner Activity Scale. Safety was assessed through the monitoring of adverse events. RESULTS: Twenty-four patients completed the 12-month follow-up. KOOS scores showed a statistically significant improvement from a mean of 61.99 at baseline to 84.32 at 12 months [95% CI: (79.25, 89.4); p<0.001]. VAS mm scores also decreased significantly, from 62.68 at baseline to 20.63 at 12 months [95% CI, (12.84, 28.41), p<0.001]. Improvements in IKDC and Tegner scores were observed but plateaued after 6 months. No adverse events were reported throughout the entire study period. CONCLUSIONS: A cycle of three intra- and peri-meniscal poly-nucleotides injections is able to provide statistically significant improvements in clinical scores up to 1 year of follow-up in patients affected by symptomatic degenerative meniscus of the knee.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-1-2.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"313-323"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of Concern.","authors":"N Authors Listed","doi":"10.26355/eurrev_202506_37270","DOIUrl":"10.26355/eurrev_202506_37270","url":null,"abstract":"&lt;p&gt;&lt;p&gt;The Publisher, in agreement with the Editor-in-Chief, is issuing this Expression of Concern to inform readers that a formal investigation is currently underway regarding a set of published articles. Despite multiple attempts to contact the corresponding authors, we have not received any response to date. Further editorial actions, such as retraction or correction, will be taken as appropriate in due course. \u0000\u0000The articles under investigation fall into the following categories. \u0000\u0000These studies report extended follow-up periods, yet were published prior to the actual conclusion of the declared follow-up. This discrepancy raises serious concerns about the validity of the timeline and outcome reporting: \u0000Liao Y, Cheng S, Xiang J, Luo C. lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1686-1692. doi: 10.26355/eurrev_201803_14581. PMID: 29630113. \u0000Yao N, Sun JQ, Yu L, Ma L, Guo BQ. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4642-4649. doi: 10.26355/eurrev_201906_18043. PMID: 31210289. \u0000Hao XZ, Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7399-7407. doi: 10.26355/eurrev_201909_18848. PMID: 31539127. \u0000Jiang J, Wu RH, Zhou HL, Li ZM, Kou D, Deng Z, Dong M, Chen LH. TGIF2 promotes cervical cancer metastasis by negatively regulating FCMR. Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):5953-5962. doi: 10.26355/eurrev_202006_21488. PMID: 32572908. \u0000\u0000These articles have been questioned as they appear to reuse identical or similar graphical elements and images from a shared library across multiple unrelated studies: \u0000Xu CF, Liu P, Tan J, Hu DF. Long noncoding RNA LINC00052 suppressed the proliferation, migration and invasion of glioma cells by upregulating KLF6. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4822-4827. doi: 10.26355/eurrev_201906_18068. PMID: 31210314. \u0000Zheng FX, Wang XQ, Zheng WX, Zhao J. Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4793-4799. doi: 10.26355/eurrev_201906_18064. PMID: 31210310.\u0000Liao J, Xie N. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A. Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1087-1092. doi: 10.26355/eurrev_201902_16998. PMID: 30779076. \u0000Lu J, Xu FQ, Guo JJ, Lin PL, Meng Z, Hu LG, Li J, Li D, Lu XH, An Y. Long noncoding RNA GAS5 attenuates cardiac fibroblast proliferation in atrial fibrillation via repressing ALK5. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7605-7610. doi: 10.26355/eurrev_201909_18883. PMID: 31539152. \u0000Shi JQ, Wang B, Cao XQ, Wang YX, Cheng ","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"287-288"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring nutraceutical solutions for prediabetes: a narrative review on the effects of banaba and chromium picolinate.","authors":"G Derosa, P Maffioli, A D'Angelo, V Foscaldi, R Piazza, M Mangrella, F Fogacci, A F G Cicero","doi":"10.26355/eurrev_202506_37275","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37275","url":null,"abstract":"<p><p>Prediabetes is an intermediary metabolic state marked by impaired glucose control, often preceding the development of type 2 diabetes (T2D). Early detection of prediabetes and intervention are critical to prevent the progression to T2D and its associated complications. This review examines the effects of nutraceuticals on regulating metabolism, with a focus on glucose control, specifically chromium picolinate (CrP) and banaba leaf extract. CrP has been extensively studied, and its role in regulating metabolism has been officially recognized. Preclinical research demonstrates its ability to improve glucose control by enhancing insulin sensitivity. These effects explain the reductions in fasting plasma glucose, elevated hemoglobin A1c, and insulin levels observed in clinical studies, particularly in patients with T2D. Banaba (Lagerstroemia speciosa) leaf extract, rich in corosolic acid and ellagitannins, has also shown promising results in improving glycemic control. As observed in preclinical studies, both banaba extract and corosolic acid exert insulin-sensitizing, glucose-lowering, and lipid-lowering properties. Clinical trials have confirmed these effects in individuals with T2D and prediabetes. Based on this evidence, combining CrP and banaba leaf extract may offer synergistic benefits in managing dysglycemia and delaying the onset of T2D in individuals with prediabetes. Only one study has evaluated the effects of the CrP and banaba extract combination, showing positive outcomes in individuals with prediabetes. Further research is needed to corroborate these preliminary findings. In conclusion, nutraceuticals like CrP and banaba leaf extract hold promise as complementary therapies to be used alongside lifestyle modifications for individuals with prediabetes.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-1-1-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"324-338"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}